Diminishing toxicity of pyrene on photosynthetic performance of soybean using Bacillus subtilis (NCIM 5594).

Polycyclic aromatic hydrocarbons are persistent organic pollutants causing serious environmental problems, being toxic to plants and difficult to remediate. Pyrene is one such extremely dangerous compound that is toxic for the environment. This study suggests the use of Bacillus subtilis (National Collection of Industrial Microorganisms [NCIM] 5594) to overcome inhibitory effects of pyrene on soybean photosynthesis. The toxicity of pyrene to soybean was evident from a significant decrease in seed germination parameters, photosynthetic performance and biomass during growth of soybean in pyrene contaminated soil. Efficiency of performance index, light absorption, trapping and electron transport were reduced in plants grown in pyrene contaminated soil while significant recovery in these parameters was observed in plants grown in pyrene+B. subtilis treated soil. Activity levels of dehydrogenase and lipase enzymes significantly recovered in pyrene+B. subtilis treated soil. After extraction of pyrene from soil and soybean plant, concentration of pyrene was lowered in pyrene+B. subtilis treated soil and plants. These findings suggest efficient degradation of pyrene by B. subtilis . About 70% degradation of pyrene was achieved in soil using B. subtilis ; thus it is a useful strain for crop improvement in pyrene polluted soil.

High Prevalence of NRTI and NNRTI Drug Resistance Among ART-Experienced, Hospitalized Inpatients.

BACKGROUND: Patients hospitalized with advanced HIV have a high mortality risk. We assessed viremia and drug resistance among differentiated care services and explored whether expediting the switching of failing treatments may be justified. SETTING: Hospitals in the Democratic Republic of (DRC) Congo (HIV hospital) and Kenya (general hospital including HIV care). METHODS: Viral load (VL) testing and drug resistance (DR) genotyping were conducted for HIV inpatients ≥15 years, on first-line antiretroviral therapy (ART) for ≥6 months, and CD4 ≤350 cells/µL. Dual-class DR was defined as low-, intermediate-, or high-level DR to at least 1 nucleoside reverse transcriptase inhibitor and 1 non-nucleoside reverse transcriptase inhibitor. ART regimens were considered ineffective if dual-class DR was detected at viral failure (VL ≥1000 copies/mL). RESULTS: Among 305 inpatients, 36.7% (Kenya) and 71.2% (DRC) had VL ≥1000 copies/mL, of which 72.9% and 73.7% had dual-class DR. Among viral failures on tenofovir disoproxil fumarate (TDF)-based regimens, 56.1% had TDF-DR and 29.8% zidovudine (AZT)-DR; on AZT regimens, 71.4% had AZT-DR and 61.9% TDF-DR, respectively. Treatment interruptions (≥48 hours during past 6 months) were reported by 41.7% (Kenya) and 56.7% (DRC). Approximately 56.2% (Kenya) and 47.4% (DRC) on TDF regimens had tenofovir diphosphate concentrations <1250 fmol/punch (suboptimal adherence). Among viral failures with CD4 <100 cells/µL, 76.0% (Kenya) and 84.6% (DRC) were on ineffective regimens. CONCLUSIONS: Many hospitalized, ART-experienced patients with advanced HIV were on an ineffective first-line regimen. Addressing ART failure promptly should be integrated into advanced disease care packages for this group. Switching to effective second-line medications should be considered after a single high VL on non-nucleoside reverse transcriptase inhibitor-based first-line if CD4 ≤350 cells/µL or, when VL is unavailable, among patients with CD4 ≤100 cells/µL.

Decline in Hepatitis C Virus (HCV) Incidence in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Progress to HCV Microelimination in the United Kingdom?

BACKGROUND: Modeling of the London hepatitis C virus (HCV) epidemic in men who have sex with men (MSM) and are living with human immunodeficiency virus (HIV) suggested that early access to direct-acting antiviral (DAA) treatment may reduce incidence. With high rates of linkage to care, microelimination of HCV within MSM living with HIV may be realistic ahead of 2030 World Health Organization targets. We examined trends in HCV incidence in the pre- and post-DAA eras for MSM living with HIV in London and Brighton, United Kingdom. METHODS: A retrospective cohort study was conducted at 5 HIV clinics in London and Brighton between 2013 and 2018. Each site reported all acute HCV episodes during the study period. Treatment timing data were collected. Incidence rates and reinfection proportion were calculated. RESULTS: A total of.378 acute HCV infections were identified, comprising 292 first infections and 86 reinfections. Incidence rates of acute HCV in MSM living with HIV peaked at 14.57/1000 person-years of follow-up (PYFU; 95% confidence interval [CI], 10.95-18.20) in 2015. Rates fell to 4.63/1000 PYFU (95% CI, 2.60 to 6.67) by 2018. Time from diagnosis to starting treatment declined from 29.8 (2013) to 3.7 months (2018). CONCLUSIONS: We observed a 78% reduction in the incidence of first HCV episode and a 68% reduction in overall HCV incidence since the epidemic peak in 2015, which coincides with wider access to DAAs in England. Further interventions to reduce transmission, including earlier access to treatment and for reinfection, are likely needed for microelimination to be achieved in this population.

Protection of PSI and PSII complexes of wheat from toxic effect of anthracene by Bacillus subtilis (NCIM 5594).

Contamination of polycyclic aromatic hydrocarbons (PAHs) in environment indicates a serious problem to the present era. These are carcinogenic and mutagenic compounds and pose a potential risk to photosynthetic organisms. The present study illustrates the protection of Photosystem I and Photosystem II complexes of wheat plant by Bacillus subtilis (NCIM 5594) from toxic effects of anthracene (ANT). Initially, Chl a fluorescence induction curve measurement revealed declined J-I and I-P phase in ANT-treated plants. Efficiency of light absorption, trapping, and electron transport was reduced in ANT-treated plants, while in ANT + Bacillus subtilis (NCIM 5594)-treated plants value of these parameters was restored. Effect of ANT and ANT + Bacillus subtilis (NCIM 5594) on energy conversion of Photosystem I and Photosystem II was measured. Quantum yield of Photosystem I (YI) and Photosystem II (YII) was decreased in the presence of ANT, while these values were recovered in ANT + Bacillus subtilis (NCIM 5594)-treated plants. Reduction in Y(II) was associated with an increase in non-regulated energy dissipation NO. Likewise the reduction of Y(I) was induced due to donor-side and acceptor-side limitation of Photosystem I caused by toxic effect of ANT. Toxic effects of ANT on electron transport rate (ETRI and ETRII) were found to be reduced in ANT + Bacillus subtilis (NCIM 5594)-treated plants. Activation of Cyclic electron flow around Photosystem I in ANT-treated plants was recovered by bacteria. It was concluded that toxic effect of ANT on Photosystem I and Photosystem II complexes was recovered by Bacillus subtilis (NCIM 5594) strain, and thus it is useful strain for crop improvement in ANT-polluted soil.

Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies.

Ritonavir and cobicistat, used as pharmacokinetic enhancers in combination with some antiretrovirals (ARVs) for the treatment of HIV, are potent inhibitors of the CYP3A4 isoenzyme. Most glucocorticoids are metabolised via the CYP3A4 pathway and iatrogenic Cushing's syndrome (ICS), with possible secondary adrenal insufficiency (SAI), is a recognised complication following co-administration with ritonavir or cobicistat. A structured approach for identifying and managing potentially affected individuals has not been established.We systematically identified patients with ICS/SAI and found substantial heterogeneity in clinical practice across three large London HIV centres. While this significant drug interaction and its complications are now well-recognised, it is apparent that there is no standardised approach to management or guidance for the general physician. Here we describe the management of ICS/SAI in our current practice, review the available evidence and suggest practice recommendations.

The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis.

Voriconazole is the second oral drug licensed for the treatment of aspergillosis. A retrospective non-comparative study was conducted in 16 patients with chronic cavitary pulmonary aspergillosis (CCPA) treated with voriconazole. All patients had failed or were intolerant of itraconazole. The duration of therapy varied from 3 days to 16.5 months. Eleven patients received at least 3 months of therapy with no significant adverse events. Overall seven (64%) patients had a response at 3 months as assessed by at least some fall in inflammatory markers, weight gain and reduction in pulmonary symptoms and two (18%) remained stable. Inflammatory markers improved in 5/11 (46%) with a mean fall in CRP of 0.08 mg/l and ESR of 12.8 mm/h. Aspergillus precipitins were quantitated by numbers of arcs and serum dilution and 11 (100%) showed improvement of at least one band or fall of titre. Total serum IgE was elevated (>200 IU/mL) in 5/11, and fell by a median of 118 kIU/l. Two patients failed therapy. Of the 17 patients, five (27%) had to discontinue therapy as a result of adverse events (three in under 1 week). Adverse events included erythematous rash (5), headaches (4), hepatotoxicity (3), photosensitive rash (3), retinal flashes (3) and neurological symptoms (3). Voriconazole is a useful alternative therapy for CCPA, with a response rate of 64%, over 3 months, and continuing partial remission of disease for much longer periods.